Glonghui, May 7 | Gacos-B (1167.HK) rose sharply by more than 30%. It now reports a two-month high of HK$2.43, with a total market value of HK$1.93 billion. The new drug marketing application (NDA) for the KRAS G12C inhibitor Glecirasib (JAB-21822) developed independently by the company has been officially submitted to the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) for second-line treatment of advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutations. In addition, multiple studies of Glecirasib as a single agent and in combination are being carried out globally.
港股异动丨加科思大涨超30% 自主研发新药上市申请正式提交
Changes in Hong Kong stocks 丨 Gacos surged more than 30%, and the application for marketing of self-developed new drugs was officially submitted
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.